Hongliang Shanghai Biomedical Technology

Hongliang (Shanghai) Biomedical Technology is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative ribonucleic acid (RNA) therapeutics and advanced drug delivery systems. The company leverages proprietary platforms in lipid nanoparticle (LNP) delivery and oligonucleotide conjugation to address unmet needs in oncology, metabolic diseases, and genetic disorders. Its lead clinical program, HLN601, is a small molecule currently in Phase 1 development for advanced malignant solid neoplasms, including breast and colorectal cancers. Hongliang is also advancing a pipeline of RNA-based therapies, including liver-targeted siRNA conjugates that utilize the asialoglycoprotein receptor (ASGPR) for precise delivery. The company's research extends to novel formulation technologies, such as supersaturated lipid delivery systems designed to enhance the stability and efficacy of poorly soluble drugs like SN38. Hongliang is supported by prominent venture capital firms, including Baidu Ventures and Beijing FOF Capital, and collaborates with leading research institutions like the Shanghai Institute of Materia Medica.